Literature DB >> 3162143

[Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].

L Dubreuil, J Devos, C Romond, A Bryskier.   

Abstract

The in vitro activity of four new quinolones against 355 obligate anaerobes was investigated. MICs were determined using the reference method of Sutter et al. [14]. The four fluorinated quinolones tested differ from nalidixic acid which is inactive on most anaerobes except for some Clostridium perfringens strains. All strains tested were inhibited by 64 and 16 mg/l pefloxacin and ofloxacin respectively. Except for Bacteroides, all strains were inhibited by 64 mg/l norfloxacin or enoxacin. Clostridium strains other than C. perfringens exhibited heterogeneity; C. difficile and C. ramosum had the highest MICs. Bacteroides fragilis proved less susceptible to fluorinated quinolones than the other obligate anaerobes. Ofloxacin showed the greatest activity, with 4 mg/l inhibiting 100% of C. perfringens and 83% of all anaerobes investigated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3162143

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  4 in total

1.  Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992.

Authors:  L Dubreuil; J Breuil; A Dublanchet; A Sedallian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

2.  [Susceptibility of clinically important Bacteroides species against enoxacin-metronidazole and enoxacin-clindamycin combinations].

Authors:  W R Heizmann; H Werner; R Schmid
Journal:  Infection       Date:  1989       Impact factor: 3.553

Review 3.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 4.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.